Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute phase of graft-vs.-host disease - PubMed (original) (raw)
Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute phase of graft-vs.-host disease
P F Piguet et al. J Exp Med. 1987.
Abstract
Lethally irradiated mice were injected with semiallogeneic, T-depleted bone marrow cells and an amount of peripheral T lymphocytes sufficient to induce graft-vs.-host disease (GVHD) becoming apparent on the second week after the graft and leading to an increasing mortality rate within the following weeks (greater than 90% mortality within 80 d). Mice receiving bone marrow cells alone had no GVHD and were used as controls. Beginning on day 8, mice with GVHD were injected weekly with 2 mg of either rabbit anti-mouse recombinant tumor necrosis factor/cachectin (TNF-alpha) IgG, or normal rabbit IgG. On the 16-18th d, mice were killed to examine the skin and intestinal lesions of the acute phase of GVHD. The anti-TNF treatment resulted in an almost complete prevention of the severe lesions seen in the mice treated with normal rabbit IgG, i.e., the skin epidermal cell necrosis, foci of lichenoid hyperplastic reactions, and loss of the hypodermic fat; in the gut dilatation with marked flattening of the villi and elevation of the crypts, with increased numbers of mitoses and isolated crypt cell necrosis. In addition to preventing these acute lesions, anti-TNF treatment resulted in a significantly decreased mortality (approximately 70% survival at 80 d). These results suggest that during acute GVHD, the activation of grafted lymphocytes leads to a local release of TNF in the cutaneous and intestinal mucosae, which induces epithelial cell alterations and increases the inflammatory reaction.
Similar articles
- Role of mast cells in early epithelial target cell injury in experimental acute graft-versus-host disease.
Murphy GF, Sueki H, Teuscher C, Whitaker D, Korngold R. Murphy GF, et al. J Invest Dermatol. 1994 Apr;102(4):451-61. doi: 10.1111/1523-1747.ep12373016. J Invest Dermatol. 1994. PMID: 7908682 - Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation.
Asai O, Longo DL, Tian ZG, Hornung RL, Taub DD, Ruscetti FW, Murphy WJ. Asai O, et al. J Clin Invest. 1998 May 1;101(9):1835-42. doi: 10.1172/JCI1268. J Clin Invest. 1998. PMID: 9576746 Free PMC article. - Idiopathic pneumonia syndrome in mice after allogeneic bone marrow transplantation.
Shankar G, Bryson JS, Jennings CD, Morris PE, Cohen DA. Shankar G, et al. Am J Respir Cell Mol Biol. 1998 Feb;18(2):235-42. doi: 10.1165/ajrcmb.18.2.2988. Am J Respir Cell Mol Biol. 1998. PMID: 9476911 - LPS antagonism reduces graft-versus-host disease and preserves graft-versus-leukemia activity after experimental bone marrow transplantation.
Cooke KR, Gerbitz A, Crawford JM, Teshima T, Hill GR, Tesolin A, Rossignol DP, Ferrara JL. Cooke KR, et al. J Clin Invest. 2001 Jun;107(12):1581-9. doi: 10.1172/JCI12156. J Clin Invest. 2001. PMID: 11413166 Free PMC article. - Pathogenesis of graft versus host disease.
Sloane JP, Dilly SA. Sloane JP, et al. Histopathology. 1988 Jan;12(1):105-10. doi: 10.1111/j.1365-2559.1988.tb01921.x. Histopathology. 1988. PMID: 3286468 Review. No abstract available.
Cited by
- Fn14 and TNFR2 as regulators of cytotoxic TNFR1 signaling.
Siegmund D, Zaitseva O, Wajant H. Siegmund D, et al. Front Cell Dev Biol. 2023 Nov 6;11:1267837. doi: 10.3389/fcell.2023.1267837. eCollection 2023. Front Cell Dev Biol. 2023. PMID: 38020877 Free PMC article. Review. - Milestones in acute GVHD pathophysiology.
Socie G, Michonneau D. Socie G, et al. Front Immunol. 2022 Dec 5;13:1079708. doi: 10.3389/fimmu.2022.1079708. eCollection 2022. Front Immunol. 2022. PMID: 36544776 Free PMC article. Review. - Translational Clinical Strategies for the Prevention of Gastrointestinal Tract Graft Versus Host Disease.
Rayasam A, Drobyski WR. Rayasam A, et al. Front Immunol. 2021 Nov 26;12:779076. doi: 10.3389/fimmu.2021.779076. eCollection 2021. Front Immunol. 2021. PMID: 34899738 Free PMC article. Review. - Hematopoietic Dysfunction during Graft-Versus-Host Disease: A Self-Destructive Process?
Müskens KF, Lindemans CA, Belderbos ME. Müskens KF, et al. Cells. 2021 Aug 10;10(8):2051. doi: 10.3390/cells10082051. Cells. 2021. PMID: 34440819 Free PMC article. Review. - Survival and Functional Immune Reconstitution After Haploidentical Stem Cell Transplantation in _Atm_-Deficient Mice.
Duecker RP, Gronau L, Baer PC, Zielen S, Schubert R. Duecker RP, et al. Front Immunol. 2021 Jun 29;12:693897. doi: 10.3389/fimmu.2021.693897. eCollection 2021. Front Immunol. 2021. PMID: 34267759 Free PMC article.
References
- Clin Immunol Immunopathol. 1973 Jul;1(4):472-98 - PubMed
- Science. 1987 Sep 4;237(4819):1210-2 - PubMed
- J Immunol. 1980 Oct;125(4):1671-7 - PubMed
- Nature. 1981 Sep 10-16;293(5828):150-1 - PubMed
- J Exp Med. 1983 Aug 1;158(2):546-58 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources